MCID: NSP003
MIFTS: 34

Nasopharyngeal Disease

Categories: Respiratory diseases

Aliases & Classifications for Nasopharyngeal Disease

MalaCards integrated aliases for Nasopharyngeal Disease:

Name: Nasopharyngeal Disease 12 15
Nasopharyngeal Diseases 54 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9561
MeSH 43 D009302
NCIt 49 C35723
SNOMED-CT 67 123952009
UMLS 71 C0027438

Summaries for Nasopharyngeal Disease

MalaCards based summary : Nasopharyngeal Disease, also known as nasopharyngeal diseases, is related to lymphoma, non-hodgkin, familial and nasopharyngeal carcinoma. An important gene associated with Nasopharyngeal Disease is PSMB9 (Proteasome 20S Subunit Beta 9), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Lidocaine and Xylometazoline have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and tonsil.

Related Diseases for Nasopharyngeal Disease

Diseases related to Nasopharyngeal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 30.1 MIR9-1 MIR324 MIR31 MIR30E MIR30A MIR29B1
2 nasopharyngeal carcinoma 29.6 PSMB9 MIR93 MIR9-1 MIR744 MIR34C MIR324
3 nasopharyngitis 11.5
4 epithelioid cell melanoma 10.6 MIR93 MIR9-1
5 endometriosis of ovary 10.6 MIR9-1 MIR30E MIR141
6 ovarian cystadenocarcinoma 10.6 MIR744 MIR30A MIR17
7 chromosomal deletion syndrome 10.6 MIR9-1 MIR185 MIR17 MIR142
8 leiomyoma, uterine 10.6 MIR30A MIR29C MIR27A MIR21
9 functioning pituitary adenoma 10.6 MIR93 MIR199A1 MIR142
10 intestinal benign neoplasm 10.6 MIR21 MIR199A1 MIR17 MIR142
11 endocrine organ benign neoplasm 10.6 MIR93 MIR21 MIR199A1 MIR142
12 papillary adenocarcinoma 10.6 MIR30E MIR30A MIR21
13 extrinsic cardiomyopathy 10.6 MIR21 MIR199A1 MIR142
14 heart valve disease 10.6 MIR29B1 MIR21 MIR199A1 MIR17
15 serous cystadenocarcinoma 10.6 MIR30A MIR199A1 MIR10B
16 uveal disease 10.6 MIR9-1 MIR199A1 MIR142 MIR125A
17 aortic valve disease 2 10.6 MIR29B1 MIR21 MIR199A1 MIR17
18 autoimmune disease of musculoskeletal system 10.6 MIR30A MIR21 MIR142 MIR125A
19 primary bacterial infectious disease 10.6 MIR93 MIR21 MIR142 MIR125A
20 polymyositis 10.6 MIR30A MIR21
21 heart conduction disease 10.6 MIR21 MIR199A1 MIR142
22 aortic disease 10.6 MIR29B1 MIR21 MIR199A1 MIR17
23 retinal vascular disease 10.6 MIR30A MIR21 MIR199A1
24 muscle cancer 10.6 MIR9-1 MIR199A1 MIR142
25 muscular dystrophy, duchenne type 10.6 MIR30E MIR30A MIR29C MIR21
26 gastrointestinal system benign neoplasm 10.6 MIR30A MIR21 MIR199A1 MIR17 MIR142
27 ovary adenocarcinoma 10.6 MIR744 MIR30A MIR17
28 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.6 MIR9-1 MIR21 MIR199A1 MIR17 MIR142
29 rectum cancer 10.6 MIR31 MIR21 MIR17 MIR125A
30 pancreatitis, hereditary 10.6 MIR199A1 MIR125A MIR10B
31 autoimmune disease of central nervous system 10.6 MIR9-1 MIR27A MIR142 MIR125A
32 chromosomal disease 10.6 MIR93 MIR9-1 MIR21 MIR185 MIR17 MIR142
33 bile duct cancer 10.6 MIR9-1 MIR31 MIR21 MIR199A1 MIR17
34 thyroid gland disease 10.6 MIR9-1 MIR199A1 MIR17 MIR142 MIR125A
35 pleural disease 10.6 MIR30E MIR29C MIR199A1 MIR17 MIR125A
36 retinal cancer 10.6 MIR9-1 MIR199A1 MIR17 MIR142 MIR125A
37 bone resorption disease 10.6 MIR93 MIR199A1 MIR142
38 pleural cancer 10.6 MIR93 MIR30E MIR29C MIR185 MIR17 MIR142
39 pulmonary disease, chronic obstructive 10.6 MIR93 MIR21 MIR199A1 MIR17 MIR142
40 demyelinating disease 10.6 MIR9-1 MIR27A MIR142 MIR125A
41 tongue disease 10.6 MIR31 MIR30A MIR21 MIR199A1 MIR185 MIR17
42 bone remodeling disease 10.6 MIR93 MIR199A1 MIR142
43 inherited metabolic disorder 10.6 MIR9-1 MIR30A MIR21 MIR199A1 MIR17 MIR142
44 mature b-cell neoplasm 10.6 MIR9-1 MIR199A1 MIR185 MIR17 MIR142 MIR125A
45 bronchial disease 10.5 MIR21 MIR17 MIR142
46 intrinsic cardiomyopathy 10.5 MIR21 MIR199A1 MIR142
47 infratentorial cancer 10.5 MIR9-1 MIR34C MIR324 MIR199A1 MIR17 MIR142
48 pediatric systemic lupus erythematosus 10.5 MIR27A MIR17
49 diffuse large b-cell lymphoma 10.5 MIR21 MIR199A1 MIR17 MIR142
50 clear cell renal cell carcinoma 10.5 MIR30A MIR21 MIR199A1 MIR185 MIR10B

Graphical network of the top 20 diseases related to Nasopharyngeal Disease:



Diseases related to Nasopharyngeal Disease

Symptoms & Phenotypes for Nasopharyngeal Disease

Drugs & Therapeutics for Nasopharyngeal Disease

Drugs for Nasopharyngeal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
3
Ephedrine Approved Phase 4 299-42-3 9294
4
Pseudoephedrine Approved Phase 4 90-82-4 7028
5
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
6 Respiratory System Agents Phase 4
7 Sodium Channel Blockers Phase 4
8 Anesthetics Phase 4
9 Pharmaceutical Solutions Phase 4
10 Nasal Decongestants Phase 4
11 Vasoconstrictor Agents Phase 4
12 Anti-Arrhythmia Agents Phase 4
13 Diuretics, Potassium Sparing Phase 4
14 Anesthetics, Local Phase 4
15
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
16
Gemcitabine Approved Phase 3 95058-81-4 60750
17
Fluorouracil Approved Phase 3 51-21-8 3385
18
Nimotuzumab Investigational Phase 3 828933-61-3, 780758-10-3
19 Antineoplastic Agents, Immunological Phase 3
20 Immunologic Factors Phase 3
21 Anti-Infective Agents Phase 3
22 Antiviral Agents Phase 3
23 Immunosuppressive Agents Phase 3
24 Antimetabolites Phase 3
25
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
26 Vaccines
27 Heptavalent Pneumococcal Conjugate Vaccine
28 Anti-Bacterial Agents
29 Antibiotics, Antitubercular

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Hypertonic Saline Enhances The Field of View of Clinicians and Ease of Procedures: A Double Blind, Randomized, Controlled Trial Comparing the Efficacy of Intranasal Hypertonic Saline, Xylometazoline, Lidocaine, and Isotonic Saline Completed NCT04214938 Phase 4
2 A Randomized Phase III Non-inferiority Study of Radiotherapy Plus Concurrent Nimotuzumab Versus Cisplatin in Stage II-III Nasopharyngeal Carcinoma Recruiting NCT03837808 Phase 3 Nimotuzumab;Cisplatin
3 GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma:a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial Recruiting NCT03840421 Phase 3 gemcitabine and cisplatin;cisplatin and fluorouracil;cisplatin
4 A Single Center 、Single Arm Phase I/II Clinical Trial of Intensity-modulated Radiotherapy Combined With Toripalimab in the Treating of Unresectable Locally Recurrent Nasopharyngeal Carcinoma. Recruiting NCT03854838 Phase 1, Phase 2 Tolipalimab
5 An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma Recruiting NCT03769467 Phase 1, Phase 2
6 Effectiveness of PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae in 2 to 5 Years Old Healthy Chinese Children. Completed NCT02133469
7 Intestinal Flora Disruption and a Novel Intestinal Biomarker Associated With Nasopharyngeal Carcinoma Completed NCT04094545

Search NIH Clinical Center for Nasopharyngeal Disease

Cochrane evidence based reviews: nasopharyngeal diseases

Genetic Tests for Nasopharyngeal Disease

Anatomical Context for Nasopharyngeal Disease

MalaCards organs/tissues related to Nasopharyngeal Disease:

40
Lung, Bone, Tonsil, Temporal Lobe

Publications for Nasopharyngeal Disease

Articles related to Nasopharyngeal Disease:

(show top 50) (show all 51)
# Title Authors PMID Year
1
Rehabilitation in an Italian thermal setting: a new therapeutic strategy for patients with musculoskeletal disability-the results of an Italian survey. 61
31342242 2020
2
Chordoma with lung metastases at initial presentation of a pediatric patient. 61
32055265 2020
3
Intestinal Flora Disruption and Novel Biomarkers Associated With Nasopharyngeal Carcinoma. 61
31867274 2019
4
TCR repertoire profiling of tumors, adjacent normal tissues, and peripheral blood predicts survival in nasopharyngeal carcinoma. 61
30155576 2018
5
Challenges of modern medicine - geriatric otolaryngology or the advantages of cooperation between an otolaryngologist and a geriatrician. 61
30920384 2018
6
Nasopharyngeal carcinoma presenting as an inconspicuous primary lesion with extensive cavernous sinus involvement and temporal lobe extension: a case report and review of literature. 61
29026572 2017
7
Paediatric nasopharyngeal cytology: a new diagnostic opportunity? 61
27039342 2016
8
Preliminary study of differentiating smears from cancerous and non-cancerous nasopharyngeal tissue using confocal Raman spectroscopy. 61
26612357 2016
9
Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma. 61
27062704 2016
10
Expression of GRIN2A in benign and malignant nasopharyngeal diseases and its clinical significance. 61
26681223 2015
11
Expression and clinical significance of LRRC4 in benign and malignant nasopharyngeal diseases. 61
26662436 2015
12
[Primary nasopharyngeal tuberculosis presenting as durative aural fullness: one case report and literature review]. 61
25219213 2014
13
Eight years of clinical findings and biopsy results of nasopharyngeal pathologies in 1647 adult patients: a retrospective study. 61
25654951 2014
14
Nasopharyngeal disease in cats: 1. Diagnostic investigation. 61
22511473 2012
15
Nasopharyngeal disease in cats: 2. Specific conditions and their management. 61
22511474 2012
16
Nasopharyngeal trichobezoar foreign body in a cat. 61
20974406 2010
17
Clinical findings, rhinoscopy and histological evaluation of 54 dogs with chronic nasal disease. 61
20706033 2010
18
[Clinical applications of magnifying laryngoscopy on nasopharyngeal examination.]. 61
20193617 2009
19
[Imaging of nasopharyngeal diseases]. 61
19639275 2009
20
[Imaging of nasopharyngeal diseases]. 61
19023557 2009
21
Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. 54
17471168 2007
22
Computed tomographic evidence of bulla effusion in cats with sinonasal disease: 2001-2004. 61
17063699 2006
23
Distribution of leucocyte subsets in the canine pharyngeal tonsil. 61
16959260 2006
24
[Diagnostic value of combined detection of CYFRA21-1 and TSGF in nasopharyngeal carcinoma]. 61
15934283 2005
25
[Otalgia as presentation of primary nasopharynx tuberculosis]. 61
16475546 2005
26
[Value of CT scan in the early diagnosis of nasopharyngeal tumor]. 61
15318638 2004
27
Capnocytophaga sp. isolated from a cat with chronic sinusitis and rhinitis. 61
14605195 2003
28
Feline inflammatory polyps: historical, clinical, and PCR findings for feline calici virus and feline herpes virus-1 in 28 cases. 61
12468312 2002
29
Vision-threatening complications of nasal T/NK lymphoma. 61
12208253 2002
30
Balloon dilation for the treatment of chronic recurrent nasopharyngeal stenosis in a cat. 61
11873954 2002
31
Lymphadenitis, trans-epidermal elimination and unusual histopathology in human rhinosporidiosis. 61
12000127 2002
32
[The thin sectional anatomy and MRI of the eustachian tube]. 61
11944475 2002
33
Nasopharyngeal diseases in cats: a retrospective study of 53 cases (1991-1998). 61
10580903 1999
34
Temporal bone tumours in patients irradiated for nasopharyngeal neoplasm. 61
10435128 1999
35
[The role of acoustic rhinometry in the evaluation of the volume of nasopharynx before and after adenoidectomy]. 61
11717890 1998
36
Nasopharyngeal cryptococcosis. 61
9258419 1997
37
[The cephalometric characteristics of the facial skeleton and base of the skull in prognathic bite]. 61
8236306 1993
38
[Effect of chronic nasopharyngeal diseases among 14-year-old students and extra-curricular factors on school performance]. 61
1788518 1991
39
MRI of the nasopharynx. 61
2645605 1989
40
Patterns of failure in nasopharyngeal cancer treated with megavoltage irradiation. 61
3088681 1986
41
Secondary lymphoma of Waldeyer's ring: natural history and association with prior extranodal disease. 61
3953968 1986
42
Hodgkin's disease in the Waldeyer's ring. 61
7361330 1980
43
The influence of nasal respiration on the function of the auditory tube. 61
84719 1978
44
[PAIN IN NASOPHARYNGEAL DISEASES]. 61
14095856 1963
45
[Relations of nasopharyngeal diseases to non-specific lung diseases]. 61
14027833 1963
46
[Treatment & prevention of acute nasopharyngeal diseases in a communal environment; a new oral bismuth derivative]. 61
13446630 1957
47
Management of some benign nasopharyngeal diseases in the adult; supplementary report. 61
13356856 1956
48
[A new aerosol in nasopharyngeal diseases: preliminary report]. 61
13168537 1954
49
Surgical treatment of benign nasopharyngeal disease in the adult. 61
14943338 1952
50
[Treatment of certain nasopharyngeal diseases with the radium emanator]. 61
15426848 1950

Variations for Nasopharyngeal Disease

Expression for Nasopharyngeal Disease

Search GEO for disease gene expression data for Nasopharyngeal Disease.

Pathways for Nasopharyngeal Disease

Pathways related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 MIR9-1 MIR34C MIR324 MIR31 MIR30E MIR30A
2 11.53 MIR9-1 MIR34C MIR29B1 MIR21 MIR125A
3 11.38 MIR34C MIR30E MIR30A MIR17
4 11.2 MIR93 MIR34C MIR27A
5 10.88 MIR34C MIR29C MIR29B1

GO Terms for Nasopharyngeal Disease

Cellular components related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 MIR93 MIR744 MIR31 MIR30E MIR30A MIR29C
2 extracellular vesicle GO:1903561 9.32 MIR93 MIR30E MIR30A MIR29C MIR29B1 MIR27A

Biological processes related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.03 MIR93 MIR9-1 MIR29C MIR29B1 MIR21
2 positive regulation of angiogenesis GO:0045766 9.86 MIR31 MIR30A MIR21 MIR199A1
3 negative regulation of cell migration GO:0030336 9.85 MIR93 MIR9-1 MIR29C MIR29B1 MIR21
4 negative regulation of inflammatory response GO:0050728 9.83 MIR31 MIR142 MIR141
5 negative regulation of angiogenesis GO:0016525 9.83 MIR29C MIR21 MIR185 MIR125A
6 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.79 MIR29C MIR29B1 MIR21
7 negative regulation of protein kinase B signaling GO:0051898 9.78 MIR34C MIR29C MIR29B1
8 negative regulation of gene expression GO:0010629 9.76 MIR93 MIR29C MIR29B1 MIR27A MIR21 MIR185
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.75 MIR27A MIR21 MIR17
10 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.72 MIR31 MIR27A MIR10B
11 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.71 MIR30E MIR21 MIR199A1
12 negative regulation of sprouting angiogenesis GO:1903671 9.69 MIR34C MIR30E MIR17
13 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.67 MIR27A MIR21 MIR10B
14 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.65 MIR21 MIR17
15 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR29B1 MIR21 MIR125A
16 regulation of DNA methylation GO:0044030 9.64 MIR29C MIR29B1
17 positive regulation of connective tissue replacement GO:1905205 9.64 MIR34C MIR199A1
18 negative regulation of matrix metallopeptidase secretion GO:1904465 9.63 MIR29B1 MIR199A1
19 negative regulation of metallopeptidase activity GO:1905049 9.62 MIR29B1 MIR199A1
20 positive regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902110 9.62 MIR29C MIR29B1
21 negative regulation of vascular endothelial growth factor production GO:1904046 9.62 MIR93 MIR199A1 MIR17 MIR125A
22 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.61 MIR34C MIR199A1 MIR17
23 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.6 MIR27A MIR21
24 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.59 MIR21 MIR17
25 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.58 MIR27A MIR185
26 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR31 MIR141 MIR125A
27 gene silencing by miRNA GO:0035195 9.58 MIR93 MIR9-1 MIR744 MIR34C MIR31 MIR30E
28 negative regulation of circulating fibrinogen levels GO:0061754 9.57 MIR29C MIR29B1
29 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.56 MIR27A MIR199A1 MIR185 MIR17
30 positive regulation of metalloendopeptidase activity GO:1904685 9.54 MIR29B1 MIR21 MIR17
31 miRNA mediated inhibition of translation GO:0035278 9.5 MIR9-1 MIR31 MIR30A MIR29B1 MIR27A MIR21

Molecular functions related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.53 MIR93 MIR9-1 MIR31 MIR30E MIR30A MIR29C
2 mRNA 3'-UTR binding GO:0003730 9.26 MIR93 MIR29B1 MIR21 MIR125A

Sources for Nasopharyngeal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....